293 related articles for article (PubMed ID: 36259611)
21. Immunotherapeutic progress and application of bispecific antibody in cancer.
Kang J; Sun T; Zhang Y
Front Immunol; 2022; 13():1020003. PubMed ID: 36341333
[TBL] [Abstract][Full Text] [Related]
22. A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.
Satta A; Grazia G; Caroli F; Frigerio B; Di Nicola M; Raspagliesi F; Mezzanzanica D; Zaffaroni N; Gianni AM; Anichini A; Figini M
Front Immunol; 2019; 10():2514. PubMed ID: 31708930
[TBL] [Abstract][Full Text] [Related]
23. A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment.
Wang L; Leach V; Muthusamy N; Byrd J; Long M
Blood Adv; 2024 Jan; 8(2):470-481. PubMed ID: 37871327
[TBL] [Abstract][Full Text] [Related]
24. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
Huang S; van Duijnhoven SMJ; Sijts AJAM; van Elsas A
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3111-3122. PubMed ID: 32989604
[TBL] [Abstract][Full Text] [Related]
25. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
26. Specific targeting immunotherapy of cancer with bispecific antibodies.
Kudo T; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Kodama H; Ichiyama M; Takemura S; Yoshida H; Saeki H; Saijyo S; Takahashi J; Tominaga T; Matsuno S
Tohoku J Exp Med; 1999 Aug; 188(4):275-88. PubMed ID: 10598685
[TBL] [Abstract][Full Text] [Related]
27. Bispecific antibodies for the treatment of breast cancer.
Dillon PM; Tushir-Singh J; Lum LG
Expert Opin Biol Ther; 2022 Aug; 22(8):1017-1027. PubMed ID: 33896311
[TBL] [Abstract][Full Text] [Related]
28. Are BiTEs the "missing link" in cancer therapy?
Suryadevara CM; Gedeon PC; Sanchez-Perez L; Verla T; Alvarez-Breckenridge C; Choi BD; Fecci PE; Sampson JH
Oncoimmunology; 2015 Jun; 4(6):e1008339. PubMed ID: 26155413
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
30. Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow.
Ahamadi-Fesharaki R; Fateh A; Vaziri F; Solgi G; Siadat SD; Mahboudi F; Rahimi-Jamnani F
Mol Ther Oncolytics; 2019 Sep; 14():38-56. PubMed ID: 31011631
[TBL] [Abstract][Full Text] [Related]
31. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
32. T-cell-engaging bispecific antibodies in cancer.
van de Donk NWCJ; Zweegman S
Lancet; 2023 Jul; 402(10396):142-158. PubMed ID: 37271153
[TBL] [Abstract][Full Text] [Related]
33. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors.
Middelburg J; Sluijter M; Schaap G; Göynük B; Lloyd K; Ovcinnikovs V; Zom GG; Marijnissen RJ; Groeneveldt C; Griffioen L; Sandker GGW; Heskamp S; van der Burg SH; Arakelian T; Ossendorp F; Arens R; Schuurman J; Kemper K; van Hall T
Nat Commun; 2024 Jan; 15(1):48. PubMed ID: 38167722
[TBL] [Abstract][Full Text] [Related]
34. Bispecific antibodies: design, therapy, perspectives.
Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
[TBL] [Abstract][Full Text] [Related]
35. [Cancer therapy using bispecific antibodies].
Kadowaki N
Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495
[TBL] [Abstract][Full Text] [Related]
36. Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy.
Acheampong DO; Adokoh CK; Ampomah P; Agyirifor DS; Dadzie I; Ackah FA; Asiamah EA
Protein Pept Lett; 2017; 24(5):456-465. PubMed ID: 28117014
[TBL] [Abstract][Full Text] [Related]
37. Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy.
Farhangnia P; Ghomi SM; Akbarpour M; Delbandi AA
Front Immunol; 2023; 14():1155778. PubMed ID: 37441075
[TBL] [Abstract][Full Text] [Related]
38. Bispecific antibodies and their applications.
Fan G; Wang Z; Hao M; Li J
J Hematol Oncol; 2015 Dec; 8():130. PubMed ID: 26692321
[TBL] [Abstract][Full Text] [Related]
39. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.
Li H; Er Saw P; Song E
Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210
[TBL] [Abstract][Full Text] [Related]
40. Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy.
Yang Y; Yang Z; Yang Y
Front Immunol; 2021; 12():686031. PubMed ID: 34305918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
